Genomic Discoveries: Precision Medicine and Personalized Approaches in Prostate Cancer Care
Author:
Bida Meshack,Mosoane Benny,Nonxuba Masibulele,Disenyane Dineo,Mongan Nigel P.,Dlamini Zodwa
Publisher
Springer Nature Switzerland
Reference137 articles.
1. Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., Mclaughlin, B., Curtis, K., Hyman, D. M., Durack, J. C., Solomon, S. B., Arcila, M. E., Zehir, A., Syed, A., Gao, J., Chakravarty, D., Vargas, H. A., Robson, M. E., Joseph, V., Offit, K., Donoghue, M. T. A., Abeshouse, A. A., Kundra, R., Heins, Z. J., Penson, A. V., Harris, C., Taylor, B. S., Ladanyi, M., Mandelker, D., Zhang, L., Reuter, V. E., Kantoff, P. W., Solit, D. B., Berger, M. F., Sawyers, C. L., Schultz, N., & Scher, H. I. (2017). Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precision Oncology, 2017, PO.17.00029. 2. Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., Mcdermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., Zhang, J., Piulats, J. M., Ryan, C. J., Merseburger, A. S., Daugaard, G., Heidenreich, A., Fizazi, K., Higano, C. S., Krieger, L. E., Sternberg, C. N., Watkins, S. P., Despain, D., Simmons, A. D., Loehr, A., Dowson, M., Golsorkhi, T., & Chowdhury, S. (2020). Rucaparib in men with metastatic castration-resistant prostate cancer Harboring a BRCA1 or BRCA2 gene alteration. Journal of Clinical Oncology, 38, 3763–3772. 3. Aggarwal, R., Wei, X., Kim, W., Small, E. J., Ryan, C. J., Carroll, P., Cooperberg, M., Evans, M. J., & Hope, T. (2018). Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. European Urology Oncology, 1, 78–82. 4. Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Fedor, H. L., Lotan, T. L., Zheng, Q., De Marzo, A. M., Isaacs, J. T., Isaacs, W. B., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., Eisenberger, M. A., & Luo, J. (2014). AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine, 371, 1028–1038. 5. Antonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Nakazawa, M., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., Eisenberger, M. A., & Luo, J. (2015). Androgen receptor splice variant 7 and efficacy of Taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncology, 1, 582–591.
|
|